Emyria Raises $4M to Expand Medibank-Funded PTSD Program Nationwide

A Groundbreaking Partnership in Mental Health Care

Emyria Limited (ASX – EMD), a pioneer in innovative mental health treatments, has secured a landmark multi-year funding agreement with Medibank Private Limited (ASX – MPL), Australia's largest private health insurer. This collaboration enables eligible Medibank customers to access Emyria’s Empax Post-Traumatic Stress Disorder (PTSD) care program at Perth Clinic without incurring out-of-pocket expenses, a first for psychotherapy-led PTSD treatment in the private insurance sector.

The deal not only removes a significant financial barrier for patients with complex mental health needs but also validates Emyria’s integrated Empax Model, which combines psychiatrist-supervised therapy, specialist care coordination, and real-world data capture to deliver personalised and measurable outcomes.

Empax Model – A Clinically Rigorous Approach

Emyria’s Empax program is designed around a psychiatrist-led, ethics-endorsed framework that rigorously screens patients and tailors treatment plans to individual clinical requirements. Treatments typically range in value from $20,000 to $30,000 per patient, reflecting the intensive and customised nature of care. The model’s integration of real-world data monitoring supports continuous improvement and robust clinical governance, setting a new standard for mental health services.

Greg Hutchinson, Emyria’s Executive Chairman, highlighted the significance of Medibank’s commitment – "Mental health has long been underfunded despite rising incidence rates. Medibank’s leadership in funding innovative psychotherapy programs is a critical step toward expanding access to effective treatments for Australians facing persistent mental health challenges."

Scaling Nationally with Strategic Capital Support

To support its ambitious national expansion, Emyria has raised $4 million through a placement priced at $0.024 per share, including participation from company directors. The funds will underpin the rollout of additional Empax Centres across key eastern states, partnerships with private hospitals and funders, and the extension of its care framework to other mental health conditions such as treatment-resistant depression.

The placement includes options exercisable at $0.05, subject to shareholder approval, reflecting investor confidence in Emyria’s growth trajectory. The company also plans to issue loyalty options to existing shareholders, further aligning interests as it scales.

Independent Validation and Future Outlook

Outcomes from the Medibank-funded program will be independently assessed by Professor Paul Fitzgerald of the Australian National University, focusing on clinical effectiveness and health economics. This research aims to build a compelling case for broader reimbursement and systemic adoption of Emyria’s model.

Dr Michael Winlo, Chief Scientific Officer, emphasized the broader implications – "This partnership signals a shift in how mental health care can be supported within Australia’s private health system. We are proud to lead this change and to offer evidence-informed therapies that address unmet needs."

With PTSD affecting roughly one in eleven Australians and disproportionately impacting women and first responders, Emyria’s scalable, data-driven approach could redefine treatment accessibility and outcomes nationwide.